275826-46-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-AMINO-3-(1-NAPHTHYL)-PROPIONIC ACID is used as an intermediate in the synthesis of pharmaceuticals for the treatment of various diseases. Its unique chiral properties allow for the development of drugs with specific therapeutic effects, particularly targeting neurological disorders and cancer.
Used in Peptide Synthesis:
In the field of peptide synthesis, (S)-3-AMINO-3-(1-NAPHTHYL)-PROPIONIC ACID serves as a building block for creating complex peptide structures. Its incorporation into peptides can modulate their biological activity and specificity, which is vital for the design of effective therapeutic agents.
Used in Materials Science:
(S)-3-AMINO-3-(1-NAPHTHYL)-PROPIONIC ACID is utilized in materials science for its unique structural and chemical properties. It can be employed in the development of novel materials with specific characteristics, such as chiral materials with potential applications in various industrial processes and technologies.
Used in Research and Development:
In the realm of research and development, (S)-3-AMINO-3-(1-NAPHTHYL)-PROPIONIC ACID is used as a key compound in exploring new drug candidates and understanding the mechanisms of action for existing pharmaceuticals. Its chiral nature provides a platform for studying the stereoselectivity of biological processes and the development of enantioselective synthesis methods.

Upstream product

• 141-82-2 malonic acid 
• 66-77-3 1-naphthaldehyde 
• 100393-41-7 3-amino-3-(1-naphthyl)propionic acid 
• 275826-33-0 3-amino-3-(1-naphthyl)propionic acid ethyl ester 

Downstream Products

• 275826-46-5 (S)-3-amino-3-(1-naphthyl)propionic acid 

Relevant academic research and scientific papers

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.

Preparation of enantiomerically enriched aromatic β-amino acids via enzymatic resolution

A range of enantiomerically enriched aromatic β-amino acids with high e.e. have been prepared via enzymatic resolution of ethyl ester derivatives. (C) 2000 Elsevier Science Ltd.

SYNTHESIS OF 6-ARYL-4-HYDROXYPIPERIDIN-2-ONES AND A POSSIBLE APPLICATION TO THE SYNTHESIS OF A NOVEL HMG-CoA REDUCTASE INHIBITOR

A series of 6-aryl-4-hydroxypiperidin-2-ones (11a-11g) were synthesised with the key step being a Dieckmann cyclisation of the appropriate methyl 3-(ethoxycarbonylacetylamino)-3-(substituted) propionate (8a-8g) and this new synthetic route was successfully applied to the synthesis of 4-hydroxy-6-(2-phenylethyl)piperidin-2-one (11h).The application of this strategy to the synthesis of the putative HMG-CoA reductase inhibitor 6--4-hydroxypiperidin-2-one (11i) was attempted, but failed during the Dieckmann cyclisation of methyl 3-(ethoxycarbonylacetylamino)- 3-propionate (8i).An alternative synthesis of a 1:1 diastereomeric mixture of (11i) was achieved by the reductive cleavage of the isoxazoline (24) with Raney nickel.The mixture of diastereoisomers (11i) was inactive in-vitro and in-vivo (rat) against HMG-CoA reductase